DHC · Diversified Healthcare Trust
$8.38
+0.01 (+0.12%)
At close · Aug 14
Market Cap
$2.03B
Shares
242.13M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$8.38
Open$8.38
Day$8.33–8.50
52W close$3.37–9.64
Avg vol 30d1.7M
Short int13.7M · 5.7% float · 10.5d
Short vol56%
Last earningsAug 4, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 3
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 3, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+20%
above
Price vs 50-day avg
−6%
below
RSI (14)
40
neutral
MACD trend
Negative
52-week position
80%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−9%
trailing
6-month return
+36%
trailing
YTD return
+73%
this year
Relative strength
+22%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.66% of float · ▲ +9.6% MoM · 10.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
233 holders — near 3-yr high, broad support
Squeeze score
67
elevated · 0–100
Fundamentals
Revenue growth
+2%
Y/Y
EPS growth
+23%
Y/Y
Balance sheet
$2.3B
net debt
Quant / Vol
risk profile
Volatility
40%
annualized · 1-yr
Max drawdown
−15%
past year
ATR
4.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 3, 2026
SHOP NOI
· Full Year 2026
Non-GAAP
$185M – $195M
Medical Office / Life Science NOI
· Full Year 2026
Non-GAAP
$94M – $98M
Total NOI
· Full Year 2026
Non-GAAP
$307M – $323M
All Other NOI
· Full Year 2026
Non-GAAP
$28M – $30M
Normalized FFO
· Full Year 2026
Non-GAAP
$135M – $150M
Adjusted EBITDAre
· Full Year 2026
Non-GAAP
$300M – $315M
Normalized FFO Per Common Share
· Full Year 2026
Non-GAAP
$0.56 – $0.62
Total Recurring Capital Expenditures
· Full Year 2026
$100M – $115M
SHOP Recurring Capital Expenditures
· Full Year 2026
$80M – $90M
Medical Office / Life Science Recurring Capital Expenditures
· Full Year 2026
$20M – $25M
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
SHOP NOI
· full year
$132M – $142M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+20%
Bullish
Price vs 50-day avg
−6%
Bearish
RSI (14)
40
Neutral
MACD trend
Negative
Bearish
52-week position
80%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $9 › 200d $7 — 50d above 200d
Institutional flow
Distributing
-1% holders QoQ · +36 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.66% of float · ▲ +9.6% MoM · 10.5 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
233 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $3
Now $8 · 80%
Range high $10
vs 200-day avg +20%
vs 50-day avg -6%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDAre non-GAAP | $82.1M | Q2 2026 | — |
| Adjusted EBITDAre to Interest Expense non-GAAP | 2.2 | Q2 2026 | — |
| Medical office and life science properties square feet | 5.6M | as of June 30, 2026 | — |
| Net Debt to Annualized Adjusted EBITDAre non-GAAP | 7.1 | Q2 2026 | — |
|
|
|||
| New and renewal leasing | 477,000 | Q2 2026 | — |
| Portfolio size | $6.3B | as of June 30, 2026 | — |
| RMR assets under management | $37B | as of June 30, 2026 | — |
| Same Property Cash Basis NOI - All Other non-GAAP | $6.93M | Q2 2026 | — |
| Same Property Cash Basis NOI - Consolidated non-GAAP | $82.96M | Q2 2026 | — |
| Same Property Cash Basis NOI - Medical Office and Life Science Portfolio non-GAAP | $24.05M | Q2 2026 | — |
| Same Property Occupancy - Medical Office and Life Science Portfolio non-GAAP | 95.8% | Q2 2026 | — |
| Same Property Occupancy - SHOP non-GAAP | 83.1% | Q2 2026 | — |
| Same Property SHOP NOI non-GAAP | $51.98M | Q2 2026 | — |
|
|
|||
| Same property SHOP NOI margin non-GAAP | 17.3% | Q2 2026 | — |
|
|
|||
| Senior living units | 23,797 | as of June 30, 2026 | — |
| Total Liquidity non-GAAP | $266.8M | Q2 2026 | — |
|
|
|||
| Total properties | 285 | as of June 30, 2026 | — |
| Consolidated NOI | $75.9M | Q1 2026 | — |
| Medical Office and Life Science Same Property Occupancy | 95.3% | Q1 2026 | — |
| New and renewal leases | 169,000 | Q1 2026 | — |
| Normalized FFO non-GAAP | $33.1M | Q1 2026 | — |
GAAP → non-GAAP reconciliationGAAP FFO 22.78M
+6.63M Incentive management fees
+3.69M Acquisition and certain other transaction related costs
+0K Gain on insurance recoveries
+0K Loss on modification or early extinguishment of debt
+0K Adjustments to reflect DHC's share of Normalized FFO attributable to a former equity method investment
= Normalized FFO 33.1M
|
|||
| Same Property Cash Basis NOI Growth | 8.6% | Q1 2026 | — |
| Same Property SHOP NOI Growth | 13.5% | Q1 2026 | — |
| Same property SHOP occupancy | 82.4% | Q1 2026 | — |
|
|
|||
| SHOP Same Property Average Monthly Rate Growth | 5.9% | Q1 2026 | — |
| SHOP Same Property Occupancy Growth | 110 | Q1 2026 | — |
| Total Cash and Cash Equivalents | $121.8M | Q1 2026 | — |
| Average monthly rates | 5.8% | Q4 2025 | — |
| Properties | 298 | as of December 31, 2025 | — |
| Same property occupancy | 94.7% | full year 2025 | — |
| SHOP NOI non-GAAP | $139.3M | full year 2025 | — |
| Total shareholder return | 112.6% | full year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
REIT - Healthcare Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
DHC
this stock
Diversified Healthcare Trust
|
$2.03B | +72.8% | +1.6% | — | 5.7% |
|
WELL
Welltower Inc.
|
$166.26B | +26.9% | +35.6% | 117.2 | 2.5% |
|
VTR
Ventas, Inc.
|
$46.94B | +18.3% | +18.5% | 169.5 | 4.6% |
|
DOC
Healthpeak Properties, Inc.
|
$14.34B | +29.3% | +4.5% | 59.4 | 3.5% |
|
OHI
Omega Healthcare Investors Inc
|
$14.10B | +4.9% | +13.2% | 16.6 | 4.2% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| DHC | -5.0% | -8.5% | +36.3% | -5.8% | +72.8% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -5.4% | -13.0% | +22.5% | -9.8% | +58.9% |
Capital returns
Latest dividend
$0.01
/ share · ex Jul 20, 2026
Paid (TTM)
$0.04
/ share · 4 payouts
Dividend yield (TTM, derived)
0.48%
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1075415
CUSIP
25525P107
13F (30d)
233 filings
226 filers
Visit website
Investor relations